Palleon Pharmaceuticals Raises $47.6 million to Develop Glycoimmune Checkpoint Inhibitors

04 October 2017

Company will target glycan-sensing checkpoints to enable both innate and adaptive immune responses to cancer WALTHAM, Mass., October 4, 2017 — Palleon Pharmaceuticals, a company focused on developing the first Glycoimmune Checkpoint Inhibitors to treat cancer, today announced the completion of a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, […]

Continue Reading